[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1110349T1 - Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη - Google Patents

Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη

Info

Publication number
CY1110349T1
CY1110349T1 CY20101100698T CY101100698T CY1110349T1 CY 1110349 T1 CY1110349 T1 CY 1110349T1 CY 20101100698 T CY20101100698 T CY 20101100698T CY 101100698 T CY101100698 T CY 101100698T CY 1110349 T1 CY1110349 T1 CY 1110349T1
Authority
CY
Cyprus
Prior art keywords
hpv
dough
vlps
synthetic
protein
Prior art date
Application number
CY20101100698T
Other languages
English (en)
Inventor
Janine T Bryan
Michelle K Brownlow
Loren D Schultz
Kathrin U Jansen
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of CY1110349T1 publication Critical patent/CY1110349T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Παρέχονται συνθετικά μόρια DNA που κωδικοποιούν την πρωτεΐνη HPV 52 L1. Ειδικότερα, η παρούσα εφεύρεση σχετίζεται με πολυνουκλεοτίδια που κωδικεύουν την πρωτεΐνη HPV 52 L1, όπου τα εν λόγω πολυνουκλεοτίδια έχουν βελτιστοποιηθεί ως προς τα κωδικόνια για να μπορεί να εκφράζεται σε υψηλά επίπεδα σε κάποιο κύτταρο ζύμης. Σε εναλλακτικές υλοποιήσεις της εφεύρεσης, η νουκλεοτιδική αλληλουχία του συνθετικού μορίου μεταβάλλεται ώστε να εξαλείφονται τα σήματα τερματισμού της μεταγραφής που αναγνωρίζονται από τη ζύμη. Τα συνθετικά μόρια μπορούν να χρησιμοποιηθούν για να παρασκευαστούν ιόμορφα σωματίδια (VLP) της HPV 52, και για να παρασκευαστούν εμβόλια και φαρμακευτικές συνθέσεις που περιέχουν τα VLP της HPV 52. Τα εμβόλια της παρούσας εφεύρεσης παρέχουν αποτελεσματική ανοσοπροφύλαξη εναντίον λοίμωξης από θηλωματοϊό μέσω των αντισωμάτων εξουδετέρωσης και της κυτταρικής ανοσίας και μπορεί επίσης να είναι χρήσιμα για τη θεραπευτική αγωγή υφιστάμενων λοιμώξεων από HPV.
CY20101100698T 2004-03-24 2010-07-26 Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη CY1110349T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55592604P 2004-03-24 2004-03-24
EP05725933A EP1730175B1 (en) 2004-03-24 2005-03-18 Optimized expression of hpv 52 l1 in yeast

Publications (1)

Publication Number Publication Date
CY1110349T1 true CY1110349T1 (el) 2015-04-29

Family

ID=34964085

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100698T CY1110349T1 (el) 2004-03-24 2010-07-26 Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη
CY2015052C CY2015052I1 (el) 2004-03-24 2015-12-07 Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2015052C CY2015052I1 (el) 2004-03-24 2015-12-07 Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη

Country Status (31)

Country Link
US (2) US7700103B2 (el)
EP (1) EP1730175B1 (el)
JP (1) JP4833962B2 (el)
KR (1) KR101203403B1 (el)
CN (1) CN1934131B (el)
AR (1) AR048191A1 (el)
AT (1) ATE466022T1 (el)
AU (1) AU2005230907C1 (el)
BE (1) BE2015C066I2 (el)
BR (1) BRPI0509079B8 (el)
CA (1) CA2560487C (el)
CY (2) CY1110349T1 (el)
DE (1) DE602005020913D1 (el)
DK (1) DK1730175T3 (el)
ES (1) ES2343255T3 (el)
FR (1) FR15C0085I2 (el)
HU (1) HUS1500062I1 (el)
IL (1) IL178140A (el)
LT (2) LTC1730175I2 (el)
LU (1) LU92903I2 (el)
MY (1) MY148656A (el)
NL (1) NL300777I2 (el)
NO (3) NO338055B1 (el)
NZ (1) NZ549898A (el)
PL (1) PL1730175T3 (el)
PT (1) PT1730175E (el)
RU (1) RU2373219C2 (el)
SI (1) SI1730175T1 (el)
TW (1) TWI349036B (el)
WO (1) WO2005097821A1 (el)
ZA (1) ZA200607575B (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
CN1869215B (zh) * 2006-05-19 2012-07-04 长春百克生物科技股份公司 一种制备人乳头瘤病毒的病毒样颗粒的方法
JP2010520874A (ja) 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
EP2479186B1 (en) * 2007-11-23 2015-08-12 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein L1 of human papilloma viruses
CN101440371B (zh) * 2007-11-23 2012-09-05 上海泽润生物科技有限公司 一种16型人乳头状瘤病毒主要衣壳蛋白l1基因
EP3705133B1 (en) * 2010-05-14 2024-06-26 Baxalta Incorporated Ospa chimeras and use thereof in vaccines
AU2011258501B2 (en) 2010-05-25 2016-07-07 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
CN102268076B (zh) * 2010-07-02 2017-04-26 厦门大学 截短的人乳头瘤病毒52型l1蛋白
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
EP2646559A2 (en) 2010-12-03 2013-10-09 MS Technologies, LLC Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
RU2445357C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
RU2445358C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN110592133A (zh) * 2013-05-17 2019-12-20 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
EP3057612B1 (en) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
CN104878022A (zh) * 2015-04-27 2015-09-02 段青姣 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
CN106701796B (zh) * 2015-08-12 2021-11-16 北京康乐卫士生物技术股份有限公司 52型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750049B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒52亚型蛋白表达
JP2023516904A (ja) 2020-02-14 2023-04-21 メルク・シャープ・アンド・ドーム・エルエルシー Ｈｐｖワクチン
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) * 2021-06-07 2023-03-31 郑州大学 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
EP4380615A1 (en) 2021-08-06 2024-06-12 Merck Sharp & Dohme LLC Hpv vaccine
JP2024532127A (ja) 2021-08-19 2024-09-05 メルク・シャープ・アンド・ドーム・エルエルシー 熱安定性脂質ナノ粒子およびその使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339729C (en) * 1988-10-26 1998-03-17 Wayne D. Lancaster Human papillomavirus type 52 dna sequences and methods for employing thesame
US5821087A (en) 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
DK0969862T3 (da) 1997-02-07 2007-02-12 Merck & Co Inc Syntetisk HIV gag-gener
JP4434479B2 (ja) 1997-07-09 2010-03-17 ザ・ユニバーシティ・オブ・クイーンズランド 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
ES2262333T3 (es) * 1998-08-14 2006-11-16 MERCK & CO., INC. Procedimiento para purificar particulas similares a virus de papilomavirus humano.
EP1105157B1 (en) 1998-08-14 2006-11-02 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
DE60016765T2 (de) * 1999-08-25 2005-11-24 Merck & Co., Inc. Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
DK1301614T3 (da) 2000-07-21 2007-04-02 Glaxo Group Ltd Codon-optimerede papillomavirus-sekvenser
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
NZ542246A (en) 2003-03-24 2007-12-21 Merck & Co Inc Optimized expression of HPV 31 L1 yeast
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast

Also Published As

Publication number Publication date
MY148656A (en) 2013-05-15
TWI349036B (en) 2011-09-21
NO338055B1 (no) 2016-07-25
HUS1500062I1 (hu) 2017-07-28
US20100035818A1 (en) 2010-02-11
PL1730175T3 (pl) 2010-09-30
SI1730175T1 (sl) 2010-08-31
BRPI0509079B1 (pt) 2020-05-19
NL300777I1 (el) 2015-12-29
TW200602490A (en) 2006-01-16
AU2005230907B2 (en) 2011-05-19
LTPA2015050I1 (lt) 2016-01-11
KR20060134120A (ko) 2006-12-27
CA2560487A1 (en) 2005-10-20
US7744892B2 (en) 2010-06-29
NO20064815L (no) 2006-10-23
JP4833962B2 (ja) 2011-12-07
AR048191A1 (es) 2006-04-05
FR15C0085I1 (el) 2016-08-01
IL178140A (en) 2010-11-30
EP1730175A1 (en) 2006-12-13
RU2373219C2 (ru) 2009-11-20
DK1730175T3 (da) 2010-08-23
ZA200607575B (en) 2008-08-27
IL178140A0 (en) 2006-12-31
FR15C0085I2 (fr) 2016-11-25
BRPI0509079A (pt) 2007-08-21
NO2017005I1 (no) 2017-01-20
CY2015052I2 (el) 2016-06-22
AU2005230907A1 (en) 2005-10-20
BE2015C066I2 (el) 2024-08-08
LTC1730175I2 (lt) 2017-05-10
ES2343255T3 (es) 2010-07-27
LU92903I2 (fr) 2016-03-08
PT1730175E (pt) 2010-06-25
ATE466022T1 (de) 2010-05-15
US7700103B2 (en) 2010-04-20
WO2005097821A1 (en) 2005-10-20
BRPI0509079B8 (pt) 2021-07-06
US20080226660A1 (en) 2008-09-18
EP1730175B1 (en) 2010-04-28
NZ549898A (en) 2009-06-26
NL300777I2 (el) 2015-12-29
DE602005020913D1 (de) 2010-06-10
NO2022050I1 (no) 2022-11-30
AU2005230907C1 (en) 2016-07-28
JP2007530040A (ja) 2007-11-01
CY2015052I1 (el) 2016-06-22
CA2560487C (en) 2013-01-29
RU2006137363A (ru) 2008-04-27
CN1934131B (zh) 2010-12-29
CN1934131A (zh) 2007-03-21
KR101203403B1 (ko) 2012-11-21

Similar Documents

Publication Publication Date Title
CY1110349T1 (el) Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη
CY1113875T1 (el) Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα
AR077396A2 (es) EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS
NO20054889D0 (no) Optimalisert uttrykking av HPV 31 LI i gjaer
SI1685243T1 (sl) Imortalizirane ptičje celične linije za produkcijo virusov
EP2484687A3 (en) Methods and compositions for seamless cloning of nucleic acid molecules
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
EP1871426A4 (en) SMALL, ACTIVATING RNA MOLECULES AND METHOD OF USE THEREOF
ATE493441T1 (de) Multispezifische deimmunisierte cd3-bindende moleküle
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
RU2011128371A (ru) Модифицированные f протеины sv и способы их применения
ATE284898T1 (de) Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
DE60024100D1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
Perenkov et al. In vitro transcribed RNA-based platform vaccines: past, present, and future
CY1110005T1 (el) Γρανζυμο β ως ενας επαγωγεας αποπτωσης κυτταρων ογκων εξαρτωμενος απο ενα hsp70/hsp70 πεπτιδιο
Chakraborty SARS-CoV-2 ORF8 gene CAA= TAA and AAA= TAA Termination Codon Mutations foun d mostly in B. 1.1. 7 Variants was Independent of Popula r L84S Point Mutations
WO2021176397A3 (en) Expression of sars-cov proteins, nucleic acid constructs, virus like proteins (vlps) and methods relevant thereto
WO2006038129A3 (en) Hepatitis c virus replication system
NO20081541L (no) Ny sjo-lus vaksine
WO2004031222A3 (en) Dna vaccine encoding at least two nonstructural early proteins of papillomavirus
Manzourolajdad et al. Novel polybasic cleavage site in SARS-CoV-2 genome is likely to induce a major change in the RNA secondary structure
WO2023097319A9 (en) Compositions and methods for inducing esr1, pi3k, her2, and her3 immune responses
EP0789563A4 (en) Vaccines against the hepatitis virus
WO2006014234A3 (en) Novel recombinant poxvirus composition and uses thereof